Faculty Opinions recommendation of Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.

2019 ◽  
Author(s):  
Corrado Girmenia
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Efficacy And Safety ◽  
Open Label ◽  
Phase 3 ◽  
Previously Treated

Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial

2011 ◽  
Vol 12 (13) ◽  
pp. 1204-1213 ◽  
Author(s):  
Thomas Elter ◽  
Liana Gercheva-Kyuchukova ◽  
Halyna Pylylpenko ◽  
Tadesuz Robak ◽  
Branimir Jaksic ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Phase 3 ◽  
Previously Treated

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study

2015 ◽  
Vol 16 (13) ◽  
pp. 1370-1379 ◽  
Author(s):  
Marinus H J van Oers ◽  
Kazimierz Kuliczkowski ◽  
Lukáš Smolej ◽  
Mario Petrini ◽  
Fritz Offner ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Open Label ◽  
Phase 3

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

The Lancet ◽  
2010 ◽  
Vol 376 (9747) ◽  
pp. 1164-1174 ◽  
Author(s):  
M Hallek ◽  
K Fischer ◽  
G Fingerle-Rowson ◽  
AM Fink ◽  
R Busch ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document